-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion, usually produced in the gastrointestinal tissues during fetal development
.
The serum level of CEA in the blood of healthy individuals is usually low (0–5 ng/ml), but may be elevated in certain non-neoplastic diseases, including inflammatory bowel disease, hepatitis, pancreatitis, lung infections , and smokingPatients(rarely more than 10 ng/ml), as well aspatients withgastrointestinal cancer, lung cancer and breast cancer
Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion, usually produced in the gastrointestinal tissues during fetal development
Although about two-thirds of patients with colorectal cancer (CRC) have elevated CEA, international guidelines do not recommend its use as a screening or diagnostic tool due to its low sensitivity and specificity
.
In metastatic CRC (mCRC), changes in serum CEA levels can be used with imaging to monitor the patient's response to systemic therapy
.
In particular, a series of retrospective studies in the past have shown that there is a correlation between the variation of CEA and the patient's chemotherapy response, indicating that it may predict disease progression (PD) and its role in avoiding CT scans
In metastatic CRC (mCRC), changes in serum CEA levels can be used with imaging to monitor the patient's response to systemic therapy
Research flow chart
Research flow chartThe results showed that the study included 1,178 CEA levels and radiology data from 434 patients
.
The best cut-off value determined according to the ROC curve shows that CEA can be distinguished from the progression of the disease by at least 120% from the lowest point.
The sensitivity is 74%, the specificity is 78%, and 92% of the radiological assessments did not appear.
PD can avoid 67% of CT scan monitoring
However, in 26% of cases, the 120% CEA threshold did not detect imaging PD
.
To improve this problem, the researchers evaluated different clinically relevant thresholds based on the optimal sensitivity cut-off value
ROC curve analysis
ROC curve analysisAll in all, the results of the study revealed that in mCRC with a baseline CEA ≥ 10 ng/mL, the level of CEA can accurately predict the patient's disease progression after the end of first-line induction therapy
.
.
The results of the study revealed that in mCRC with a baseline CEA ≥ 10 ng/mL, the level of CEA can accurately predict the patient's disease progression after the end of the first-line induction therapy
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients.
Leave a message here